Related references
Note: Only part of the references are listed.Responsiveness and predictive value of EDSS and MSFC in primary progressive MS
J. J. Kragt et al.
NEUROLOGY (2008)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis
J. J. Kragt et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite
ELJ Hoogervorst et al.
MULTIPLE SCLEROSIS (2004)
Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis
X Montalban
MULTIPLE SCLEROSIS JOURNAL (2004)
Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)
JC Hobart et al.
NEUROLOGY (2003)
Interferon β-1a in primary progressive MS -: An exploratory, randomized, controlled trial
SM Leary et al.
NEUROLOGY (2003)
Primary progressive multiple sclerosis: a 5-year clinical and MR study
GT Ingle et al.
BRAIN (2003)
Quantitative functional measures in MS: What is a reliable change?
SR Schwid et al.
NEUROLOGY (2002)
Share Paper
